D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy by Shailesh V Shrikhande et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Shrikhande et al. World Journal of Surgical Oncology 2013, 11:31
http://www.wjso.com/content/11/1/31RESEARCH Open AccessD2 lymphadenectomy is not only safe but
necessary in the era of neoadjuvant
chemotherapy
Shailesh V Shrikhande1*†, Savio G Barreto1†, Sanjay D Talole2, Kumar Vinchurkar1, Somashekar Annaiah1,
Kunal Suradkar1, Shaesta Mehta3 and Mahesh Goel1Abstract
Background: Patients with locally advanced resectable gastric cancers are increasingly offered neoadjuvant
chemotherapy (NACT) following the MAGIC and REAL-2 trials. However, information on the toxicity of NACT, its
effects on perioperative surgical outcomes and tumor response is not widely reported in literature.
Methods: Analysis of a prospective database of gastric cancer patients undergoing radical D2 gastrectomy over 2
years was performed. Chemotherapy-related toxicity, perioperative outcomes and histopathological responses to
NACT were analyzed. The data is presented and compared to a cohort of patients undergoing upfront surgery in
the same time period.
Results: In this study, 139 patients (42 female and 97 male patients, median age 53 years) with gastric
adenocarcinoma received NACT. Chemotherapy-related toxicity was noted in 32% of patients. Of the 139 patients,
129 underwent gastrectomy with D2 lymphadenectomy, with 12% morbidity and no mortality. Major pathological
response of primary tumor was noted in 22 patients (17%). Of these 22 patients, lymph node metastases were
noted in 12 patients. The median blood loss and lymph node yield was not significantly different to the 62 patients
who underwent upfront surgery. Patients who underwent upfront surgery were older (58 vs. 52 years, P <0.02), had
a higher number of distal cancers (63% vs. 82%, P <0.015) and a longer hospital stay (11 vs. 9 days, P <0.001).
Conclusions: Perioperative outcomes of gastrectomy with D2 lymphadenectomy for locally advanced, resectable
gastric cancer were not influenced by NACT. The number of lymph nodes harvested was unaltered by NACT but,
more pertinently, metastases to lymph nodes were noted even in patients with a major pathological response of
the primary tumor. D2 lymphadenectomy should be performed in all patients irrespective of the degree of
response to NACT.
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Gastric cancer is an aggressive disease with a poor sur-
vival rate even in surgically resected patients owing to
locoregional recurrence [1,2]. In India, gastric cancer is
relatively common and is the second most common
cause of cancer-related deaths among men and women
[3], with 5-year survival rates of just 27% for surgically* Correspondence: shailushrikhande@hotmail.com
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distribution, and reproduction in any mediumresected patients [4]. Morbidity and mortality rates
following gastric cancer surgery vary around the world
depending on the extent of gastric resection and
lymphadenectomy [5-8]. While mortality rates have
decreased, there continues to be considerable morbidity
after surgery [9]. In 2006, Cunningham et al. [10]
published a landmark trial demonstrating a significant
improvement in 5-year survival rates with perioperative
chemotherapy for patients with oesphagogastric cancer
compared to surgery alone (36% vs. 23%, P = 0.009).
This trial was followed by another randomized con-
trolled trial in France [11], demonstrating similartral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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with the use of neoadjuvant chemotherapy (NACT) as
part of perioperative chemotherapy for oesphagogastric
cancer. Following these trials [10,11], perioperative
chemotherapy for gastric cancer has been increasingly
practiced around the world [9].
While the MAGIC trial [10] demonstrated no differ-
ence in perioperative morbidity with and without
NACT (46% vs. 45%), the two subsequent randomized
controlled trials [11,12] demonstrated a trend towards a
higher, although non-significant, post-operative mor-
bidity rate in patients who received NACT (26% vs.
19% and 27% vs. 16%, respectively) suggesting the pos-
sible risk of increased complications [1]. Another non-
randomized study by An et al. [13] also found a high
incidence of surgical complications following preopera-
tive chemotherapy.
One of the limitations of the trials [10-12], as well as
three non-randomized studies from the USA [14], Spain
[15] and Korea [13], has been the non-uniform perform-
ance of D2 lymphadenectomy in the studies. Therefore,
there is a need to critically evaluate perioperative surgi-
cal outcomes of radical gastrectomy with D2 lympha-
denectomy in this modern era of NACT.
We decided to objectively analyze the perioperative
outcomes for standardized D2 gastrectomies following
NACT owing to conflicting reports of perioperative
outcomes from the six previous studies [10-15]. We
have previously reported low morbidity and mortality
rates following standardized D2 lymphadenectomy in
chemotherapy-naive gastric cancer patients in India [8].
The aims of the current study were: 1) to analyze the
toxicity of the chemotherapeutic regimens; 2) to deter-
mine the effect of NACT on downstaging cancers prior
to resection; and 3) to determine perioperative surgical
outcomes after NACT.
Methods
Patients undergoing surgery for gastric tumors at the
Department of Gastrointestinal and Hepato-Pancreato
-Biliary Surgical Oncology, Tata Memorial Hospital,
Mumbai, India between February 2010 and August 2012
were evaluated retrospectively from a prospectively
maintained database. All surgeries were performed by,
or under the supervision of, the consultant surgeons in
the unit (SVS, MG, SGB).
Preoperatively, all patients were investigated in the same
manner with routine blood investigations, including blood
counts, liver and renal functions, electrocardiogram and
an endoscopy with biopsy. A multi-detector computed
tomography (MDCT) triphasic scan of the abdomen and
pelvis was performed. Endoscopic ultrasonography was
only performed for staging patients with suspected early
gastric cancers.Planning for NACT
Since 2010, the Tata Memorial Hospital has adopted the
routine use of a NACT regimen as part of perioperative
chemotherapy for patients with locally advanced (non-
metastatic) but resectable gastric cancer. The laboratory
(biochemistry and pathology) and imaging results of every
patient were discussed at the joint meeting of the Gastro-
intestinal Disease Management Group, in accordance with
routine policy. The indications for directing patients to-
wards NACT were: 1) biopsy-proven gastric adenocarcin-
oma; 2) MDCT scan indicative of tumor stage (≥T3),
perigastric fat stranding, with or without nodal metastases;
and 3) no evidence of distant metastases on MDCT scan
of the abdomen and pelvis.
The patients were divided into two groups for compara-
tive reasons. Group 1 comprised patients who received
NACT followed by surgery, and complete details of their
chemotherapy regimens and toxicity, as well as periopera-
tive surgical outcomes was available (n = 139 patients).
Group 2 comprised patients who underwent upfront rad-
ical gastrectomy for adenocarcinoma (n = 67) due to
reasons such as gastric outlet obstruction (n = 43 of 67) or
tumors considered early based on joint clinic decisions
(n = 24 of 67).
In 40 patients, the chemotherapy was administered
elsewhere. These patients were referred to our unit for
surgery, and complete details of regimens and toxicity
were unavailable. The perioperative surgical data of
these patients is presented separately.
NACT regimen
The protocol consisted of administering either 5 days of
5-fluorouracil (5-FU) for patients with partial gastric
outlet obstruction or capecitabine for patients without
gastric outlet obstruction, instead of the regular MAGIC
trial regimen (21-day infusion of 5-FU) [10].
The regimens employed were based on inferences of
the REAL-2 trial [16,17] owing to the reduced toxicity
noted in the trial and included the following drugs:
epirubicin (E) 50 mg/m2 (day 1), cisplatin (C) 60 mg/m2
(day 1), 5-FU (F) 650 mg/m2 (days 1 to 5), oxaliplatin
(O) 130 mg/m2 (day 1), capecitabine (X) 1000 mg/m2
twice daily (days 1 to 14), docetaxel (D) 50 mg/m2
(day 1); in the following combinations: EOX, ECX, EOF,
ECF, CAPOX, EO and DCF.
Definition of chemotherapy-related toxicity
All adverse events and toxic effects were graded according
to the National Cancer Institute (NCI) Common Toxicity
Criteria, version 3.0.
Re-staging/assessment of response after NACT
The response to treatment was recorded according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
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stable disease (SD), complete regression/response (CR),
disease progression (DP) or partial regression/response
(PR), after a joint clinic meeting of the Gastrointestinal
Disease Management Group.
Surgical technique
All patients were restaged with an MDCT scan 2 to 4
weeks after completion of the NACT, at which time a
final decision was made for surgery. All procedures were
performed in a standardized manner and included prox-
imal, subtotal (distal) and total gastrectomies for gastric
cancer, along with a D2 lymphadenectomy, as adopted
from the technique practiced by the National Cancer
Center, Tokyo, Japan, since 2002 [2,19]. A subtotal (dis-
tal) gastrectomy was preferred for tumors located in the
pyloro-antral region or in the distal body, provided a 4
cm proximal free margin could be obtained. A proximal
gastrectomy was performed for lesions in the proximal/
mid-body or cardia of the stomach in which at least half
of the distal stomach could be preserved. Total gastrec-
tomy was reserved for lesions in the body or antrum in
which adequately free (4 to 5 cm), proximal and distal
margins could not be obtained, lesions on the greater
curvature with potential metastases to 4sb station lymph
nodes [20], and for linitis plastica lesions. We do not
routinely perform a prophylactic splenectomy with a
total gastrectomy owing to the risk of increased morbid-
ity coupled with the lack of level I evidence to support a
survival benefit from the performance of such a proced-
ure [21]. Clinical, pathological and surgical details were
recorded.
All patients were administered an antibiotic dose of
cefoperazone + sulbactam 2 gm at induction of anesthesia
and this antibiotic was continued up to the third
postoperative day.
Perioperative mortality was defined as deaths taking
place while the patient was still admitted in hospital.
Deaths were included irrespective of whether they arose
as a result of the surgery or other causes (for example
cardiac-related deaths). Postoperative complications have
been defined as per our previous publication (anastomotic
and duodenal stump leaks were detected either by drain-
age of bilious contents in the tube drains placed in the
abdominal cavity or signs and symptoms suggestive of
intra-abdominal sepsis, or both [8]) and delayed gastric
emptying (DGE) as per the International Study Group of
Pancreatic Surgery (ISGPS) [22]. All complications were
graded according to the Clavien-Dindo classification [23].
Final pathological staging
Final pathological staging was based on the 7th edition
of the American Joint Committee on Cancer (AJCC) sta-
ging for gastric cancer [24].Statistical analyzes
All statistical analyzes were performed using the Statistical
Product and Service Solutions (SPSS) version 14.0 for
Windows (IBM SPSS Statistics, IBM, Armonk, NY, USA).
Nominal data is provided as number (%) and continuous
data as median (range). Non-parametric tests, Mann–
Whitney U test for continuous variables and chi-square
test for categorical variables were used. All the tests were
conducted at 5% significance level.
Results
Figure 1 provides a full breakdown of the 302 patients who
underwent surgery for gastric tumors in the study period.
Of the 179 patients who received NACT, complete data on
chemotherapy-related toxicity was available for 139 patients
and these patients were included in the final analysis as
Group 1. However, for the purpose of completeness, the
data of the remaining 40 patients is also provided in the
results section. Sixty-seven patients (Group 2) underwent
upfront gastrectomy with D2 lymphadenectomy.
Data of Group 1 (n = 139)
Epidemiological data (n = 139 patients)
The cohort comprised 42 female and 97 male patients
with a median age of 53 years (range 22 to 77 years).
Based on endoscopy, the locations of the tumors were:
gastro-esophageal region (30 patients), pyloric-antrum
(69 patients), body (24 patients), fundus (14 patients)
and whole stomach, linitis plastica-type (2 patients).
NACT details (including toxicity, n = 139)
Table 1 summarizes the complete data of the patients
who received NACT with regimens, number of cycles,
patients in whom the regimen had to be changed or
cycles reduced, and associated toxicity.
In this cohort, 133 patients (96%) completed NACT.
Six patients (4%) could complete only two cycles of
NACT due to toxicity. Toxicities were noted in 45
patients (32%). In 2 patients (2%) the protocol had to be
changed from ECX to ECF and EOX to EOF because of
persistent vomiting resulting from partial gastric outlet
obstruction.
Of the 139 patients who underwent NACT, the post-
chemotherapy imaging (in comparison to the pre-
chemotherapy scan images) indicated PR in 85 patients
(61%), SD in 40 patients (29%), CR in 5 patients (4%)
and DP in 9 patients (6%) (Figure 2).
Surgical details (n = 139 patients)
Based on the radiological findings, 138 patients under-
went either a staging laparoscopy with or without lapar-
otomy (12 patients), or direct exploratory laparotomy
(126 patients). One patient developed metastases on im-
aging and was directed to palliative chemotherapy.
Figure 1 Breakdown of the entire cohort of 302 patients who underwent surgery for gastric tumors in the study period. NACT,
neoadjuvant chemotherapy.
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patients (91%). Of the remaining 12 patients, a palliative
antecolic, posterior gastrojejunostomy was performed in
4 patients; while 8 patients had inoperable disease and
no procedure could be offered. Details of the surgeries
are provided in Table 2. Six patients (4.7%) required
intraoperative blood transfusions.
Post-operative morbidity and mortality
In this cohort, 15 patients (12%) had complications. These
included DGE (grade A, 2 patients and grade B, 4 patients),
2 patients each had suspected duodenal stump leaks,
prolonged drain outputs and respiratory complications, and
1 patient each had a collection, a retrogastric hematoma
and surgical site infection.
Three patients were re-explored, the 2 patients with
suspected duodenal stump leaks and the patient with the
retrogastric hematoma. While a defect in the duodenal
stump was evident in 1 patient (this was sutured, periton-
eal lavage and drains were placed), no clear defect at the
duodenal stump or the gastrojejunal anastomosis was
found in the other patient. A thorough peritoneal lavage
was performed and drains were placed. Both patients
made an uneventful recovery. In the third patient who
developed a hematoma at exploration, there was a ret-
rogastric hematoma and the spleen appeared ischaemic
with no pulsations in the distal splenic artery. A splenec-
tomy was performed and the patient recovered unevent-
fully after an 8-day stay in the intensive care unit.
In this series, 12 patients had grade I, 1 patient had
grade IIIb and 2 patients had a grade IVa complication,
as per the Clavien-Dindo classification.There was no mortality in this series.
Histopathological data of patients with resected cancers
after NACT (n = 126)
All patients had adenocarcinomas. Details of the histo-
pathology are provided in Table 3. A major pathological
response was noted in the primary tumor in 22 patients
(17.4%), no residual primary tumor in 15 patients (12%)
and scanty foci of tumor in 7 patients (6%). Of the 22
patients, however, tumor was detected in the lymph
nodes of 12 patients (55%).
In 5 patients (4%), two distal and three proximal
margins demonstrated foci of tumor on final histopath-
ology (R1 resections). Thus, in 121 patients (96%), a
curative (R0 resection) could be achieved. In 4 of the 5
patients in whom the distal and proximal margins had
shown tumor foci on final histopathology, four spe-
cimens were sent for frozen section intraoperatively and
were reported to have clear margins. In the case of the
fifth patient, the surgery was performed as an after-hour
emergency for a perforated gastric cancer and intra-
operative frozen section was unavailable.
Clinico-pathological data of patients with unavailable
chemotherapy-related toxicity data (n = 40) is presented
in Table 4.
Data of Group 2 (n = 67)
Although 67 patients underwent an exploratory laparot-
omy with a curative intent, 5 patients were found to
have advanced disease not amenable to a curative resec-
tion and only a palliative gastrojejunsotomy was
performed. Therefore, 62 patients underwent curative
Table 1 Details of the neoadjuvant chemotherapy (NACT) regimens administered and associated toxicity
Regimen Total number of
patients (n = 139)
Number of patients who completed the NACT
(n = 133)a
Toxicity grade
EOX3 87 83 (1 patient received 2 additional cycles) Tolerated toxicities
Grade I vomiting (5 patients)
Grade I diarrhea (1 patient)
Grade I vomiting and diarrhea (2 patients)
Grade I skin and hair toxicity (1 patient)
Grade I neutropenia (1 patient)
Grade II vomiting (3 patients)
Grade II diarrhea (1 patient)
Grade II vomiting and diarrhea (1 patient)
Grade III hand-foot syndrome (1 patient)
Grade IV diarrhea (1 patient)
Grade IV thrombocytopenia (2 patients)
Toxicities resulting in alterations in regimen
Grade I diarrhea, and on and off febrile illness
(1 patient, resulted in reduced cycles)
Grade III fatigue (1 patient, resulted in reduced cycles)
Grade III diarrhea (1 patient, resulted in reduced cycles)
Grade IV vomiting and diarrhea (1 patient, resulted
in reduced cycles)
Grade III vomiting (1 patient, protocol changed to
EOF after 1 cycle)
ECF3 24 23 (1 patient received an additional cycle of docetaxel and
oxaliplatin)
Grade I diarrhea (2 patients)
Grade I vomiting (1 patient)
Grade II vomiting and diarrhea (1 patient)
Grade IV mucositis (2 patients)
Grade IV diarrhea (1 patient)
Grade IV vomiting and diarrhea (1 patient)
Toxicities resulting in alterations in regimen
Grade IV diarrhea (1 patient, resulted in reduced cycles)
EOF3 9 8 Grade I vomiting (1 patient)
Grade I diarrhea (2 patients)
Toxicities resulting in alterations in regimen
Grade IV mucositis (1 patient, resulted in 25% dose
reduction and reduced cycles)
Grade III febrile neutropenia (1 patient, resulted in
20% dose reduction)
CAPOX3 7 7 Grade 1 nausea, vomiting (2 patients)
EO3 1 1
DCF 6 6 (3 patients received 3 cycles each and 1 patient each
received 4, 5 and 6 cycles, respectively)
Anemia after 1 cycle and grade 1 diarrhea after 2
cycles (1 patient)
Grade II febrile neutropenia (1 patient)
Grade III diarrhea (1 patient)
1 patient developed chicken pox while on
chemotherapy
ECX3 5 5 Toxicities resulting in alterations in regimen
Grade 1 nausea and vomiting (1 patient, protocol
changed to ECF after 1 cycle)
aSix patients received reduced cycles due to toxicity. E, epirubicin 50 mg/m2 (day 1); C, cisplatin 60 mg/m2 (day 1); F, 5-FU 650 mg/m2 (days 1 to 5); O, oxaliplatin
130 mg/m2 (day 1); X, capecitabine 1000 mg/m2 twice daily (days 1 to 14); D, docetaxel 50 mg/m2 (day 1).
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Figure 2 Axial computed tomography scan sections. (a) A patient with gastric cancer demonstrating thickening of the walls of the mid-body
along the lesser curvature (short bold, white arrow). (b) Axial section of the same patient demonstrating complete radiological resolution after 3
cycles of NACT. NACT, neoadjuvant chemotherapy.
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is provided as a comparison in Table 2. Histopathological
data for comparison with Group 1 is provided in Table 3.
Comparison between Group 1 and 2
Table 2 provides a comparison of the demographic and
perioperative surgical data between groups 1 and 2.
Patients who underwent upfront surgery (Group 2)
tended to be older (P <0.02), had significantly higher dis-
tal tumors (P <0.015) and had a longer post-operative
hospital stay (P <0.001).
Discussion
The findings of this study, one of the largest, prospect-
ive, non-randomized series and the first from India,
indicate that NACT does result in a pathological
downstaging of the tumor permitting a curative surgical
resection in up to 96% of patients. NACT resulted in
toxicity of varying grades in 32% of patients. However,Table 2 Perioperative details comparing patients who underw
group 1 with patients who underwent upfront surgery (n = 62
Resected patients from g
Median age in years (range) 53 (22 to 77)





Median blood loss in ml (range) 500 (150 to 1700)
Median units of blood transfused (range) 0 (0 to 2)
Median lymph nodes (range) 16 (1 to 53)
Morbidity rate 12% (15)
Mortality rate 0% (0)
Median duration of hospital stay in days (range) 9 (6 to 28)such toxicity resulted in a change of regimen or a reduc-
tion in the number of cycles in only 5.7% of patients.
The findings of the REAL-2 study [16,17] have provided
numerous less toxic options to the regimen proposed by
the MAGIC trial [10]. NACT did not appear to ad-
versely affect the perioperative surgical outcomes such
as median blood loss, number of units transfused, length
of hospital stay, morbidity and mortality.
The three randomized controlled trials [10-12] as well
as three non-randomized studies [13-15], did not clearly
indicate the number of patients undergoing D1 and D2
lymphadenectomy along with the perioperative out-
comes specific to these subsets of patients.
In Table 2, we compared the perioperative outcomes
between the patients who underwent surgery after
NACT with upfront surgery. These two groups are not
readily comparable due to the fact that patients under-
going upfront surgery generally do so owing to their
distally-located tumors being within the stomach leadingent radical resections following NACT (n = 126) from
) from group 2
roup 1 (n = 126) Resected patients from group 2 (n = 62)
58 (28 to 82) P <0.02




400 (50 to 900) P <0.24
0 (0 to 2) 0.88 P <0.88
18 (3 to 39) P <0.25
22.6% (14) P <0.056
0% (0) -
11 (6 to 43) P <0.001
Table 3 Histopathological data comparing patients who underwent radical resections following NACT (n = 126) from
group 1 with patients who underwent upfront surgery (n = 62) from group 2
Resected patients from group 1 (n = 126) Resected patients from group 2 (n = 62)
Final pathology
Carcinoma in situ - 1 (2%)
Well-differentiated adenocarcinoma 4 (3%) 5 (8%)
Moderately-differentiated adenocarcinoma 27 (21%) 17 (27%)
Poorly differentiated adenocarcinoma 57 (45%) 33 (53%)
Signet ring cell adenocarcinoma 16 (13%) 6 (10%)
Microscopic foci of adenocarcinoma 7 (6%) -






Perineural invasion present 22 (17%) 9 (14.5%)
Lymphovascular invasion present 45 (36%) 36 (58%)
Median number of lymph nodes harvested (range) 16 (1 to 53) 18 (3 to 39)
Median number of positive nodes (range) 1 (0 to 22) 2 (0 to 22)
Lymph node ratio (range) 0.07 (0 to 1.0) 0.14 (0 to 0.95)
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sult is that these patients have a poor tolerance to
chemotherapy in the neoadjuvant setting. They may also
be nutritionally depleted resulting in the observed higher
morbidity rates. The data also indicates that the patients
offered upfront surgery tended to be older in age (with
the potential for pre-existing co-morbidities), which
could also have contributed to an increased morbidity
and resultant longer hospital stay.
Our data suggests that NACT does not affect the
lymph node yield at the time of surgery (16 vs. 18,
P <0.25). This is in contrast to a recent publication by
Wu et al. [25] who found a reduced lymph node yield
(<15 harvested lymph nodes) following NACT compared
to patients who underwent upfront surgery for gastric
cancer (7.7% vs. 24.1%). The lower median number of
lymph nodes reported in the final histopathological ana-
lysis in our series compared to series from Japan [7] and
Korea [26] cannot be readily explained considering that
the technique of lymphadenectomy performed by us
is based entirely on the procedure described by the
National Cancer Centre, Tokyo. We can only conjecture
that this may be related to the other important variable
in improving lymph node yield, the diligence of the
pathologist [27]. The development of disease-centric
management groups comprising organ/disease-specific,
dedicated surgeons and pathologists, as has been the
policy at our institution, will help clarify these aspects in
the near future [28].In our study, there are multiple regimens employed
for NACT. Rather than perceiving this as a weakness of
the study, this is in fact a reflection of our experience
with Indian patients and their inability to tolerate the
standard chemotherapeutic regimens prescribed for gas-
tric cancer in other parts of the world. Thus, we had to
resort to different combinations in order to tailor the
chemotherapeutic regimen to the tolerability of the patient.
A NACT protocol of EOX, as per our own experience,
with an interval of 4 to 6 weeks between chemotherapy
and surgery, would constitute the most useful schedule to
be followed.
On comparing our study with the other three non-
randomized studies [13-15], one of the major findings
reported in the other three studies is a high morbidity
(29.3 to 38%, compared to 12% in our study). Possible
reasons for the lower morbidity in our series could include
the lack of radiotherapy in the neoadjuvant setting as well
as the increased experience with the standardized tech-
nique of D2 lymphadenectomy in a high-volume centre.
Major pathological response to the neoadjuvant therapy
was reported only in the study by Valenti et al. [15] to be
33% (47.6% in the chemoradiotherapy arm and 13.3% in
the chemotherapy arm). The major pathological response
in our study (in which only chemotherapy was used) was
17%, which is similar to the response rate in the study by
Valenti et al. [15]. The perceived benefit of better patho-
logical response noted by the combination of chemother-
apy and radiotherapy compared to chemotherapy alone in
Table 4 Clinico-pathological data of patients with unavailable chemotherapy-related toxicity data
Patient data (n = 40)
Clinical data
Median age in years (range) 52.5 (23 to 85)












Median blood loss in ml (range) 500 (100 to 1000)
Median units of blood transfused (range) 0 (0 to 1)
Morbidity ratea 16.6% (5)
Mortality rate 0% (0)
Median duration of hospital stay in days (range) 9 (3 to 35)




Poorly differentiated adenocarcinoma 11
Signet ring cell adenocarcinoma 7
Microscopic foci of adenocarcinoma 1






Perineural invasion present 6 (20%)
Lymphovascular invasion present 13 (43%)
Median number of lymph nodes harvested (range) 15 (1 to 36)
Median number of positive nodes (range) 1 (0 to 14)
Positive microscopic resection margin 4 (13%)
aComplications included duodenal stump leaks (2 patients), delayed gastric emptying grade B (1 patient), pneumonia (1 patient) and intra-abdominal collection
(1 patient).
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since the surgical morbidity rates are significantly higher
(30.9% in the study by Valenti et al., compared to 12% in
the present study).
An interesting finding in our series has been the iden-
tification of positive lymph nodes (55%) even in patients
who demonstrated a major pathological response of the
primary tumor to chemotherapy on histopathology.
These data indicate that administration of NACT doesnot obviate the need for a complete radical resection
and D2 lymphadenectomy. Although this observation is
based on a relatively small cohort of patients, its signifi-
cance cannot be undermined pending larger series in the
future.
Our centre constitutes a referral unit and as a result
complete data of all the patients who may have received
chemotherapy outside the hospital, prior to referral, was
not very clear in terms of toxicities. Hence these patients
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demiological and surgical data of these patients has been
presented, which is not different from the larger cohort.
At the time of the study period, the only accepted in-
dication for staging laparoscopy was in patients with T3
or T4 gastric cancer without evidence of lymph node or
distant metastases on high quality preoperative imaging
[29]. This clinical scenario was very uncommon in our
setting and hence the selective use of staging laparos-
copy in our series.
Surgeons have harbored concerns regarding operating
on patients whose tissues have been treated with neo-
adjuvant chemotherapy/chemoradiotherapy. However,
these subjective difficulties need to be objectively assessed
in terms of perioperative outcomes. From our study we
can infer: 1) based on the objective comparison of our
perioperative surgical outcomes of upfront surgery versus
surgery after NACT, there is no further increase in mor-
bidity or mortality; and 2) there is no significant disease
progression to preclude surgery after NACT based on our
observation that only 12 of 139 patients (8.6%) were ineli-
gible for a radical resection. These findings should con-
vince surgeons dealing with gastric cancer to move
towards NACT followed by gastrectomy with D2 lym-
phadenectomy as an evidence-based standard of care for
gastric cancer.
Conclusions
Perioperative outcomes of gastrectomy with D2 lympha-
denectomy for locally advanced resectable gastric cancer
are not influenced by NACT. Furthermore, the quality
and radicality remains unaffected. The number of lymph
nodes harvested was unaltered by NACT and, more im-
portantly, metastases to lymph nodes were noted even in
patients with major pathological response of the primary
tumor. D2 lymphadenectomy should be performed even
in patients with a good objective response of the primary
tumor to NACT.
This is the first study from India to demonstrate no
change in morbidity, mortality and lymph node yield
in patients undergoing gastrectomy with D2 lympha-
denectomy in the post-MAGIC trial era compared to
outcomes in patients undergoing upfront surgery prior
to the introduction of NACT protocols. More import-
antly, lymph node metastases were noted even in
patients who demonstrated a major pathological re-
sponse of the primary tumor to NACT supporting the
need for D2 lymphadenectomy in all patients.
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